MorphicLogo.jpg
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
May 06, 2020 16:05 ET | Morphic Therapeutic
Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as CFO and COO ...
MorphicLogo.jpg
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
April 29, 2020 16:15 ET | Morphic Therapeutic
WALTHAM, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
April 07, 2020 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
March 17, 2020 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference
February 28, 2020 08:00 ET | Morphic Therapeutic
WALTHAM, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MorphicLogo.jpg
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
February 27, 2020 16:05 ET | Morphic Therapeutic
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the α4β7 Integrin and Potential Treatment for Inflammatory Bowel Disease
February 14, 2020 11:29 ET | Morphic Therapeutic
Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate Mechanism of action demonstrated in in vitro and in vivo models ...
MorphicLogo.jpg
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 08, 2020 12:00 ET | Morphic Therapeutic
WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic to Present at the Jefferies 2019 London Healthcare Conference
November 18, 2019 16:15 ET | Morphic Therapeutic
WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
November 12, 2019 16:24 ET | Morphic Therapeutic
MORF-720, αvβ6-targeted oral integrin inhibitor IND now anticipated in the second half of 2020α4β7-targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020Morphic ends third...